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The role of dexamethasone to reduce delayed emesis following highly emetogenic chemotherapy is proven, but there is less evidence
of benefit after mild–moderately emetogenic regimens. Here, we develop and evaluate a Dexamethasone Symptom Questionnaire
(DSQ) to assess the side effects of dexamethasone in the week after patients receive moderately emetogenic chemotherapy. The
DSQ was first optimised with the aid of a focus group. Sixty patients receiving oral dexamethasone for prophylaxis of delayed emesis
after moderately emetogenic chemotherapy for cancer completed and then evaluated the DSQ. Patients reported that the DSQ was
clearly worded and addressed items important to them. Patients receiving dexamethasone reported moderate–severe problems with
insomnia (45%), indigestion/epigastric discomfort (27%), agitation (27%), increased appetite (19%), weight gain (16%) and acne (15%)
in the week following chemotherapy. The side effects of dexamethasone may outweigh its benefits when used with moderately
emetogenic chemotherapy. A randomised, double-blind crossover trial is underway to determine the effect of dexamethasone on
nausea and vomiting, and the impact of side effects of dexamethasone and of nausea and vomiting on quality of life.
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Dexamethasone given before chemotherapy has been shown to
reduce acute nausea and vomiting (Cassileth et al, 1983; Kris et al,
1989; Smith et al, 1991; Smyth et al, 1991; Roila et al, 1991, 1992;
Hesketh et al, 1994, 1995; Adams et al, 1995; Latreille et al, 1995;
Lofters et al, 1997; Warr, 1997; Ioannidis et al, 2000). Dexametha-
sone given after highly emetogenic chemotherapy reduces delayed
emesis (1997a,b; Herrstedt et al, 1998; Ioannidis et al, 2000) and is
recommended by all the antiemetic guidelines (1997a,b, 1999;
Gralla et al, 1999, 2001; Koeller et al, 2002). However, dexametha-
sone has side effects and there is less evidence for its benefit when
given after mild–moderately emetogenic regimens (Roila et al,
1996, 2005; Ballatori et al, 1997).
Many patients complain of side effects associated with the use
of dexamethasone despite it being reported as ‘well tolerated’ in
antiemetic studies (Aapro et al, 1984). However, the side effects of
dexamethasone are not evaluated specifically in most antiemetic
studies, possibly because it is difficult to distinguish them from the
effects of the chemotherapy, of concomitant antiemetics or of the
intravenous dexamethasone given for control of acute emesis
before chemotherapy.
Here we report the development and initial evaluation of the
Dexamethasone Symptom Questionnaire (DSQ), a 13-item self-
report questionnaire designed to measure the incidence and
severity of symptoms and signs that may be caused by
dexamethasone in the week following treatment.
Our aim was to optimise and validate the DSQ, and to provide
pilot information about the incidence and severity of side effects
that may be due to oral dexamethasone when used for delayed
antiemetic prophylaxis after moderately emetogenic chemotherapy
in cancer patients.
MATERIALS AND METHODS
The DSQ is a self-report questionnaire designed to be completed 1
week after moderately emetogenic chemotherapy, and patients are
asked to rate the incidence and severity of any of the side effects
within the preceding 7 days. Using the framework of Kirshner
and Guyatt (1985), it is intended as a descriptive measurement (to
determine incidence and severity of side effects), as well as
evaluative (to examine changes in side effects due to dexametha-
sone between cycles of chemotherapy).
Development of the DSQ
The authors performed item generation based on their own clinical
experience and after literature review and informal consultation
with medical oncologists and non-physicians involved in cancer
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scare. A questionnaire containing 13 questions was generated and
responses formatted using a four-point Likert scale (1¼not at all,
2¼a little bit, 3¼quite a bit, 4¼very much) (Edwards, 1983).
Two small focus groups of patients, who were receiving
moderately emetogenic chemotherapy and dexamethasone for
delayed emetic prophylaxis, were conducted by facilitators (JV and
KC). Patients completed the DSQ individually and then the group
discussed each individual item, focusing on whether the items were
important to the patients, and whether additional items should be
included; they also commented on the clarity and wording of the
questions and the options for response.
Evaluation of side effects of dexamethasone
Following its optimisation, the DSQ was administered as a self-
report questionnaire on one occasion, 1 week after chemotherapy,
to a total of 60 patients. At the completion of the questionnaire, all
patients were asked to provide a brief written evaluation of the
DSQ. They were asked to comment on whether the questions were
clear and easily understandable, whether they had experienced any
other symptoms that were not listed and to suggest improvements
to the questionnaire.
Demographic information was collected from the patient, and
details of antiemetics and chemotherapy were collated from the
medical records. Eligibility criteria for the patients were 418 years
of age and receiving oral dexamethasone after moderately
emetogenic chemotherapy for cancer as an outpatient at Princess
Margaret Hospital. Patients with a major pre-existing psychiatric
history, drug or alcohol abuse, severe co-morbidity or patients
receiving steroids for indications other than for emetic control
were excluded. Approval for the trial was obtained from the
hospital Research Ethics Board, and informed consent was
obtained from all participating patients.
Scoring of the DSQ
The questionnaire comprises two constructs, which are scored
separately with each item being scored from 0 to 3 (i.e. not at
all¼0 points; 2 a little bit¼1 point, etc.). The main construct
includes nine items that evaluate the following side effects of
dexamethasone: insomnia, gastro-oesphageal reflux, agitation,
increased appetite, weight gain, acne, hiccups, oral candida and
depression on ceasing medication. Scores for this construct can
range from 0 to 27. The second construct includes two items that
evaluate the severity of nausea and vomiting (scores range from 0
to 6). A higher score indicates worse symptoms. Weight loss and
decreased appetite are not included in either subscore but can be
used as supportive information. Each individual item can also be
scored independently to indicate the severity of the symptom
within a group of patients.
Statistical analysis
Demographic variables, treatment and side effects are presented as
frequency data with number and percentage, together with 95%
confidence intervals for the side effects. The Spearman rank
coefficient was used to evaluate correlation between items of the
DSQ. The remainder of the data is presented using descriptive
statistics.
RESULTS
Development of the DSQ
The original questionnaire contained 13 items. Item reduction was
performed using a clinimetric approach (Feinstein, 1983). After the
focus groups and expert review (by three medical oncologists and
an experienced cancer nurse), a question related to indigestion was
judged to be redundant and was deleted, and an item related to
depression was added. Minor adjustments in wording were made
to two questions. The final version of the DSQ is shown in Table 1.
Patients in the focus groups reported that the DSQ addressed all
the items important to them and that the questions were clear and
concise.
Patient characteristics
Sixty cancer patients receiving moderately emetogenic chemo-
therapy (as defined by the Perugia guidelines (1998)) completed
the DSQ 1 week after chemotherapy. There were 46 female and 14
Table 1 Dexamethasone symptom questionnaire
Dexamethasone questionnaire Patient number: &
Patient Initials:
&&&
Date of birth (day, month, year):
&&&
Today’s date (day, month, year):
&&&
We are interested in some things about you and your health. Please answer all the questions by circling the number that best applies to you. There are no ‘‘right’’ or
‘‘wrong’’ answers. The information that you provide will remain strictly confidential.
DURING THE WEEK AFTER YOUR CHEMOTHERAPY:
Not at all A little Quite a bit Very much
1. Did you have indigestion/heartburn/reflux or discomfort in the upper abdomen? 1 2 3 4
2. Did you have trouble getting to sleep? 1 2 3 4
3. Have you felt nauseated? 1 2 3 4
4. Have you vomited? 1 2 3 4
5. Have you lacked appetite? 1 2 3 4
6. Have you had increased appetite? 1 2 3 4
7. Have you had hiccups? 1 2 3 4
8. Have you lost weight? 1 2 3 4
9. Have you gained weight? 1 2 3 4
10. Have you felt agitated/nervous? 1 2 3 4
11. Have you had a rash/acne on your face? 1 2 3 4
12. Have you had thrush/yeast infection in your mouth? 1 2 3 4
13. Did you experience feelings of depression on stopping the dexamethasone? 1 2 3 4
Dexamethasone Symptom Questionnaire study
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smale patients aged 28–78 years (median and mean 53 years).
Before chemotherapy, all patients received dexamethasone (98%
intravenously (10 or 20mg) and one patient orally) and 90% had
i.v. granisetron 1mg. All patients received oral dexamethasone for
delayed prophylaxis (35 received 4mg twice daily for 2 days, 13
received 4mg twice daily for 3 days, seven received 4mg twice
daily for 1 day and the remainder received 4mg b.i.d. for 1–2 days
and then a tapering dose). A total of 80% were also prescribed oral
granisetron for delayed prophylaxis (generally 2mg daily for 2
days) and a minority took prochlorperazine (35%), domperidone
(15%) or metoclopramide (3%), as required for nausea or
vomiting.
The tumour sites and chemotherapy regimens are listed
in Table 2. The majority of the patients had breast, colorectal or
ovarian cancer, and 50% were being treated for metastatic disease.
The most common regimens were cyclophosphamide, epirubicin
and 5-fluorouracil (CEF); adriamycin and cyclophosphamide
(AC)7followed by a taxane; and oxaliplatin, 5-fluorouracil
and folinic acid (FOLFOX). The mean number of chemotherapy
cycles completed was four and there was a mixture of chemo-
therapy naı ¨ve and pretreated patients (Eight patients were
receiving their first cycle of chemotherapy, 17 cycle 2, 10 cycle 3,
5 cycle 4 and the remainder had received five or more cycles of
chemotherapy).
Side effects associated with dexamethasone
The percentage of patients experiencing each of the symptoms, in
the week following moderately emetogenic chemotherapy, and
their self-reported severity rating according to the DSQ are shown
in Table 3. Patients receiving dexamethasone reported moderate–
severe problems with: insomnia (45% (95% CI 32–58%)),
indigestion/epigastric discomfort (27% (95% CI 16–40%)), agita-
tion: (27% (95% CI 16–40%)), increased appetite (19% (95% CI
10–30%)), weight gain (16% (95% CI 8–29%)) and acne (15%
(95% CI 7–27%)), in the week following their chemotherapy. Only
15 patients (25%, 95% CI 15–38%) reported no or only mild side
effects on all items, while 19 (32%, 95% CI 20–45%) reported at
least three moderate–severe symptoms. Sixteen patients (27%,
95% CI 16–40%) reported moderate–severe symptoms for at least
two of the following four: insomnia, gastro-oesphageal reflux
disease, agitation and depression; only 21 patients (35%, 95% CI
23–48%) did not report moderate–severe symptoms for this
cluster of side effects.
Moderate–severe vomiting was reported by five patients (8%,
95% CI 3–18%) and nausea by 17 patients (28%, 95% CI 17–41%).
Eleven patients (18%, 95% CI 10–30%) scored X3/6 on the emetic
subscale, which included five patients (8%, 95% CI 3–18%)
scoring 4 or above.
The only missing data were single items in two of the 60
questionnaires (one for hiccups and one for agitation), for which
the symptom response was conservatively assigned to be ‘not at
all.’ Five additional patients completed the questionnaire, but as
they had not received oral dexamethasone after their chemo-
therapy, they were ineligible and excluded from analysis.
Correlation between items of the DSQ
In order for the DSQ to be a useful clinical instrument, it should
demonstrate correlation between items that one would expect to be
correlated, and to discriminate between items that are expected
to be relatively independent. Table 4 indicates Spearman rank
correlation co-efficients between items of the DSQ. As expected,
nausea and vomiting (Spearman r¼0.38, P-value¼0.003), and
increased appetite and weight gain (Spearman r¼0.50, P-
valueo0.001) were strongly correlated. Items such as insomnia
and acne showed, as expected, a low coefficient of correlation
(Spearman r¼0.10, P-value¼0.47). The nausea/vomiting sub-
score was positively associated with the dexamethasone side-effect
subscore (Spearman r¼0.17); however, this association was not
statistically significant (P-value¼0.19).
Table 2 Patient characteristics
Number (%)
Total 60
Male/female 14(23)/46(77)
Age (years)
Mean/median 53/53.5
Range 28–78
Diagnosis
Breast cancer 32 (53)
Colorectal cancer 16 (27)
Gynaecological cancer 6 (10)
Lung 2 (3)
Prostate 1 (2)
Unknown primary 3 (5)
Treatment
Adjuvant 30 (50)
Metastatic 30 (50)
Smoking status
Non-smoker 31 (52)
Ex-smoker 20 (33)
Smoker 8 (13)
Not available 1 (2)
Alcohol consumption
Nil 39 (65)
p100g/week 13 (22)
4100g/week 5 (8)
Not available 3 (5)
Chemotherapy regimen
a
AC7T 14 (23)
CEF 13 (22)
FOLFOX 8 (13)
XELIRI 3 (5)
Other 16 (27)
aAC7T¼Adriamycin and cyclophosphamide7-taxane; CEF¼cyclophosphamide,
epirubicin, 5-fluorouracil; FOLFOX¼oxaliplatin, 5-fluorouracil and folinic acid;
XELIRI¼capecitabine (Xeloda) and irinotecan.
Table 3 Symptoms reported during the week after chemotherapy in
patients receiving oral dexamethasone (n¼60)
Percent affected
Symptom
Not at
all
A
little
Quite a
bit A lot
Insomnia 27 28 20 25
Indigestion/reflux/epigastric discomfort 35 38 15 12
Agitation 43 30 20 7
Increased appetite 50 32 12 7
Weight gain 60 23 13 3
Facial rash/acne 68 17 10 5
Depression on ceasing dexamethasone 75 18 3 3
Hiccups 75 17 8 0
Oral candida 87 10 2 2
Anorexia 45 23 28 3
Nausea 25 47 21 7
Vomiting 80 12 3 5
Dexamethasone Symptom Questionnaire study
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sDISCUSSION
The number of patients with moderate–severe symptoms that may
be due to dexamethasone is substantial, with approximately half
reporting insomnia and a quarter reporting each of gastro-
oesophageal reflux and agitation of moderate–severe severity.
Many patients experienced multiple symptoms. These results
suggest that dexamethasone may have a substantial deleterious
effect on quality of life (QOL).
Most patients receiving moderately emetogenic chemotherapy
have well-controlled emesis: for example, (Gralla, 1997) reported
rates of complete control of acute emesis in 90% and delayed
emesis in 80–95%. In this study, 8% of patients reported
moderate–severe vomiting and 28% reported moderate–severe
nausea. Vomiting and nausea can decrease QOL, but QOL depends
on multiple additional factors. Osoba (1997), Osoba et al (1997)
and Rusthoven et al (1998) found a significant decline in several
domains of QOL following chemotherapy in patients who reported
no nausea and vomiting, although to a lesser extent than in
patients with nausea and/or vomiting. The QOL of patients with
minimal nausea or vomiting might be affected more by the side
effects of the antiemetic treatment.
The DSQ has good face and content validity and sensibility. The
purpose and framework is clearly delineated, and it has been tested
in the population for which it is ultimately intended. The burden
on respondents is low, with the questionnaire taking 2–3min to
complete. Patients and experts report that it is simple yet
comprehensive. Further evaluation of construct validity and of
test–retest reliability is required for full validation. Repeated
measures will be evaluated in our future study.
The major limitation of the current study is that it is not
possible to determine which side effects were caused by the
dexamethasone given after chemotherapy, by the intravenous
dexamethasone given before chemotherapy, by the chemo-
therapy itself, or by other antiemetics or concomitant medications.
However, the symptoms are characteristic of those due
to dexamethasone (and not of other drugs received by the
patients).
The purpose of this pilot study was to determine whether
sufficient patients suffer side effects from oral dexamethasone to
warrant performing a definitive trial of its use. Because of the high
rate of reported symptoms, a randomised double-masked placebo-
controlled crossover trial is now underway to compare the use of
dexamethasone with placebo for delayed emetic prophylaxis
following moderately emetogenic chemotherapy. The trial will
evaluate the impact of both dexamethasone and of nausea
and vomiting on QOL and determine patients’ preference for
either dexamethasone or placebo. In this trial, the two items
regarding weight gain and weight loss will be omitted from the
DSQ, as patients will be weighed to gain more accurate
information on changes in weight. We will also omit the ‘decreased
appetite’ item. The nausea and vomiting items could also be
omitted in future studies if daily emetic dairies or more
comprehensive emetic questionnaires were being used as part of
an antiemetic study, and only information on the dexamethasone
side effects was required.
The DSQ is a simple, brief instrument, which can be used to
assess the side effects associated with dexamethasone. These side
effects may outweigh the benefits of dexamethasone when used
with moderately emetogenic chemotherapy.
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